ten Bosch John Roderick sold $138K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 1,416 shares of BillionToOne, Inc. (BLLN) at $97.54 ($0.14M total) on 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Sep 11, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting minimal immediate market reaction.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming dilution events or financing not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Sep 11 2026

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

Officer John Roderick sold 1,416 shares for $138,116 via a 10b5-1 plan.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is small relative to market cap and disclosed via pre‑arranged plan.

Market effects

None; insider sale does not affect sector trends.

None; company is micro‑cap with limited broader impact.

None

Counterpoint

Sale could signal insider concern, but 10b5‑1 plans are routine.

Key entities

  • BillionToOne, Inc.

    Issuer of the disclosed insider transaction.

  • John Roderick

    SVP of Laboratory Operations who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.